Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer.
Xueying WuChenyang ZhangHenghui ZhangPublished in: Current oncology (Toronto, Ont.) (2022)
IES has a predictive value for response to neoadjuvant trastuzumab therapy and independent prognostic value for HER2-positive breast cancer.